<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603770</url>
  </required_header>
  <id_info>
    <org_study_id>LY02405/CT-USA-102</org_study_id>
    <nct_id>NCT02603770</nct_id>
  </id_info>
  <brief_title>Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers</brief_title>
  <official_title>A Single Site, Randomized Open Label Cross-Over Study to Compare Pharmacokinetic Profiles (PK) of XueZhiKang (XZK) Capsules Versus Lovastatin Tablets in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luye Pharma Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luye Pharma Group Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare laboratory tests profiles of a botanic drug
      XueZhiKang (XZK) 300 mg capsules versus a marketed drug Lovastatin 20 mg tablets in healthy
      male volunteers between 18 and 50 years of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty (20) healthy male subjects will be enrolled and assigned to either XZK group or
      Lovastatin group at a 1:1 ratio at one site in the USA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC for the Pharmacokinetics (PK) of XZK</measure>
    <time_frame>12 days</time_frame>
    <description>PK Samples drawn at 0 (within 30 minutes prior to dosing), 0.5, 1,2,3,4 (+/- 5 min), 6,8,12 and 24 hour (+/- 15 min) after dosing on Day 1 and Day 11</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Lipid Metabolism Disorder</condition>
  <arm_group>
    <arm_group_label>XueZhiKang (XZK)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XueZhiKang (XZK) 1200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lovastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lovastatin 20 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XueZhiKang</intervention_name>
    <arm_group_label>XueZhiKang (XZK)</arm_group_label>
    <other_name>XZK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovastatin</intervention_name>
    <arm_group_label>Lovastatin</arm_group_label>
    <other_name>Mevacor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of giving informed consent and complying with study procedures;

          -  Male subjects between the ages of 18 and 50 years, inclusive;

          -  Considered healthy by the PI, based on a detailed medical history, physical
             examination, clinical laboratory tests, 12-lead ECG and vital signs;

          -  Nonsmoker, defined as not having smoked or used any form of tobacco in more than 6
             months before screening;

          -  Body Mass Index (BMI) of 19 to 32 kg/m2 inclusive and body weight not less than 50 mg;

          -  Willing and able to adhere to study restrictions and to be confined at the clinical
             research center.

        Exclusion Criteria:

          -  Clinically significant past history of gastrointestinal, cardiovascular,
             musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic,
             bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug
             hypersensitivity;

          -  History or presence of malignancy other than adequately treated basal cell skin
             cancer;

          -  Clinically relevant illness within one month prior to the screening visit or at
             screening visit that may interfere with the conduct of this study;

          -  Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface
             antigen (HBsAG) or hepatitis C antibody;

          -  A history of seizure. However, a history of febrile seizure is allowed;

          -  A hospital admission or major surgery within 30 days prior to screening;

          -  Participation in any other investigational drug trial within 30 days from the last
             dosing of other trials to screening;

          -  A history of prescription drug abuse, or illicit drug use within 6 months prior to
             screening;

          -  A history of alcohol abuse according to medical history within 6 months prior to
             screening;

          -  A positive screen for alcohol, drugs of abuse;

          -  Tobacco use within 6 months prior to screening based on subject report;

          -  Subjects with hypersensitivity to lipid-lowering agents;

          -  Subjects who have participated in a previous clinical study of XZK;

          -  An unwillingness or inability to comply with food and beverage restrictions during
             study participation;

          -  Donation or blood collection of more than 1 unit (approximately 450 ml) of blood (or
             blood products) or acute loss of blood during the 90 days prior to screening;

          -  Use of prescription or over-the-counter (OTC) medications, and herbal (including St.
             John's Wort, herbal teas, garlic extracts) within 14 days prior to dosing (Note: Use
             of acetaminophen at &lt; 3g/day is permitted until 24 hours prior to dosing).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon LI, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Luye Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NRC Research Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Lipid Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lovastatin</mesh_term>
    <mesh_term>L 647318</mesh_term>
    <mesh_term>Dihydromevinolin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

